Retatrutide Titration Protocol
Gradual metabolic/fat-loss titration minimizing GI side effects
Overview
Retatrutide is a triple GLP-1/GIP/glucagon receptor agonist. As with other incretin-class compounds, tolerability (nausea, GI upset) rather than raw dose ceiling is what typically paces titration in community practice — most protocols step the dose up slowly over months rather than jumping to an effective dose immediately.
Dosing schedule
Informational only — not medical advice.
| Phase | Amount | Frequency | Timing | Route |
|---|---|---|---|---|
| Weeks 1–4 | 1 mg | 1x/week | — | subcutaneous injection |
| Weeks 5–8 | 2 mg | 1x/week | — | subcutaneous injection |
| Weeks 9–12 | 4 mg | 1x/week | — | subcutaneous injection |
| Weeks 13+ | 4–8 mg | 1x/week | Titrate further only if prior dose is well-tolerated | subcutaneous injection |
Administration
Reconstitute with bacteriostatic water per the product's labeled concentration. Inject subcutaneously (abdomen/thigh), rotating sites weekly. Same day each week is standard to keep a consistent interval.
Cycle length
16 weeks on. Typically run as an extended, continuous protocol rather than short cycles, given the slow titration curve.
Precautions
- GI side effects (nausea, constipation, reflux) are the primary tolerability issue — slow titration is the main mitigation.
- Contraindicated with any personal/family history of medullary thyroid carcinoma or MEN2 syndrome (class-wide precaution for GLP-1-pathway agonists).
- Not appropriate for anyone with a history of pancreatitis without medical guidance.
- Significant appetite suppression can lead to inadequate protein/micronutrient intake if not deliberately managed.